About Us

Pipeline

Press Releases

Location

Pipeline

  • Pipeline

Pipeline

Indications Target Pipeline Early Discovery Preclinical Phase 1 Clinical Trial Phase 2 Clinical Trial Partner
Non-Small Cell Lung Cancer (NSCLC) EGFR C797S
Mutation		 JIN-A02 Tyrosine kinase inhibitor

US FDA /MFDS IND /TFDA IND Approval1)
Orphan Drug Designation Application Submitted2)

-
HER2 Exon20
insertion
Mutation		 JIN-A04
(YH42946) Tyrosine kinase inhibitor

Orphan Drug Designation Application Submitted3),
Technology Transfer (to Yuhan Corporation) 4)
EGFR/HER2 Exon20
insertion
Mutation		 JIN-A01 Tyrosine kinase inhibitor

-
Solid Tumor HSP90 JIN-001 HSP90 inhibitor 

Solid Tumor

 MD Anderson
Glioblastoma

Glioblastoma: Collaborative
Research with MD Anderson
Glioblastoma HDAC6 JIN-002 HDAC inhibitor

-
New JIN-NOVA AI-based Novel Drug Development Platform TBD

Indications Target Pipeline Stage Partner
Non-Small Cell Lung Cancer (NSCLC) EGFR C797S JIN-A02 Tyrosine kinase inhibitor

Phase 1 Clinical Trial

US FDA /MFDS IND /TFDA IND Approval1) Orphan Drug Designation Application Submitted2) 		-
HER2 Exon20
insertion		 JIN-A04
(YH42946) Tyrosine kinase inhibitor

Preclinical

Orphan Drug Designation Application Submitted3), Technology Transfer (to Yuhan Corporation)4)
EGFR/HER2 Exon20 insertion JIN-A01 Tyrosine kinase inhibitor

Preclinical injury

 -
Solid Tumor HSP90 JIN-001 HSP90 inhibitor 

Phase 1 Clinical Trial

Solid Tumor

Preclinical

Glioblastoma: Collaborative Research with MD Anderson
MD Anderson
Glioblastoma
Glioblastoma HDAC6 JIN-002 HDAC inhibitor 

Preclinical

 -
New JIN-NOVA
AI-based Novel Drug Development Platform 		TBD

Early Discovery

1) US FDA: Nov 2022 Approval, MFDS : Mar 2023 Approval, Thai FDA : May 2023 Approval
2) Orphan Drug Designation Application Submitted: Aug 2023
3) Orphan Drug Designation Application Submitted: Aug 2022
4) Technology Transfer (to Yuhan Corporation): May 2023